Barclays initiated coverage of Ideaya Biosciences (IDYA) with an Overweight rating and $40 price target The firm sees two “value-inflecting” data readouts from the company by the end of 2025: the Phase 1 data for DLL3 antibody-drug conjugate in small cell lung cancer and the pivotal data for darovasertib plus crizotinib in uveal melanoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Hold Rating for IDEAYA Biosciences Amid Favorable Financial Terms and Developmental Risks
- Ideaya Biosciences price target raised to $74 from $72 at JPMorgan
- Ideaya Biosciences submits IDE892 IND application to FDA
- IDEAYA Biosciences: Strategic Partnership with Servier Bolsters Financial Outlook and Validates Darovasertib Potential
- IDEAYA Biosciences: Strategic Partnerships and Financial Strength Underpin Buy Rating